Key result
The subcutaneous implantable cardioverter-defibrillator (S-ICD) avoids transvenous lead risks but remains limited by inappropriate shocks due to cardiac oversensing.
Why the study?
While the subcutaneous implantable cardioverter-defibrillator avoids transvenous lead risks, inappropriate shocks due to cardiac oversensing remain a significant limitation.
Highlights the need to optimize the interaction between subcutaneous implantable cardioverter-defibrillators and leadless pacemakers to mitigate risks like inappropriate shocks from T-wave oversensing.
Vector reprogramming resolved P- and T-wave oversensing in this case; leaves open optimal screening and programming strategies to minimize inappropriate S-ICD shocks.
The subcutaneous implantable cardioverter-defibrillator (S-ICD) is an effective therapy for preventing sudden cardiac death in appropriately selected patients. 1 As a fully extrathoracic and extravascular system, it avoids the risks associated with transvenous leads, such as fracture or endocarditis. 2 However, inappropriate shocks—often due to cardiac oversensing, particularly T-wave oversensing—remain a significant limitation. 3
No takes yet. Share an insight, caveat, or question.
Sánchez-Somonte et al. (2025) conducted an editorial in Sudden cardiac death. Subcutaneous implantable cardioverter-defibrillator (S-ICD) was evaluated. The subcutaneous implantable cardioverter-defibrillator (S-ICD) avoids transvenous lead risks but remains limited by inappropriate shocks due to cardiac oversensing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: